|
1
|
Droller MJ: Bladder cancer:
State-of-the-art care. CA Cancer J Clin. 48:269–284. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riese DJ II, van Raaij TM, Plowman GD,
Andrews GC and Stern DF: The cellular response to neuregulins is
governed by complex interactions of the erbB receptor family. Mol
Cell Biol. 15:5770–5776. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee H and Maihle NJ: Isolation and
characterization of four alternate c-erbB3 transcripts expressed in
ovarian carcinoma-derived cell lines and normal human tissues.
Oncogene. 16:3243–3252. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee H, Akita RW, Sliwkowski MX and Maihle
NJ: A naturally occurring secreted human ErbB3 receptor isoform
inhibits heregulin-stimulated activation of ErbB2, ErbB3 and ErbB4.
Cancer Res. 61:4467–4473. 2001.PubMed/NCBI
|
|
6
|
Memon AA, Sorensen BS, Meldgaard P, Fokdal
L, Thykjaer T and Nexo E: The relation between survival and
expression of HER1 and HER2 depends on the expression of HER3 and
HER4: A study in bladder cancer patients. Br J Cancer.
94:1703–1709. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Memon AA, Sorensen BS, Melgard P, Fokdal
L, Thykjaer T and Nexo E: Expression of HER3, HER4 and their ligand
heregulin-4 is associated with better survival in bladder cancer
patients. Br J Cancer. 91:2034–2041. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nielsen TO, Borre M, Nexo E and Sorensen
BS: Co-expression of HER3 and MUC1 is associated with a favourable
prognosis in patients with bladder cancer. BJU Int. 115:163–165.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fisher C: TNM classification of malignant
tumours. J Clin Pathol. 51:84–85. 1998.
|
|
10
|
Yin H and Leong AS: Histologic grading of
noninvasive papillary urothelial tumors: Validation of the 1998
WHO/ISUP system by immunophenotyping and follow-up. Am J Clin
Pathol. 121:679–687. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Munk M, Memon A, Poulsen SS, Borre M, Nexo
E and Sorensen BS: The HER4 isoform JM-a/CYT2 relates to improved
survival in bladder cancer patients but only if the estrogen
receptor α is not expressed. Scand J Clin Lab Invest. 73:503–513.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schooler K and Wiley HS: Ratiometric assay
of epidermal growth factor receptor tyrosine kinase activation.
Anal Biochem. 277:135–142. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atienza JM, Zhu J, Wang X, Xu X and Abassi
Y: Dynamic monitoring of cell adhesion and spreading on
microelectronic sensor arrays. J Biomol Screen. 10:795–805. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fattore L, Marra E, Pisanu ME, Noto A, de
Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto
PA and Ciliberto G: Activation of an early feedback survival loop
involving phospho-ErbB3 is a general response of melanoma cells to
RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J
Transl Med. 11:1802013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Memon AA, Munk M, Nexo E and Sorensen BS:
Calcium-induced apoptosis is delayed by HER1 receptor signalling
through the Akt and PLCγ pathways in bladder cancer cells. Scand J
Clin Lab Invest. 71:45–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin SH, Lee YC, Choueiri MB, Wen S, Mathew
P, Ye X, Do KA, Navone NM, Kim J, Tu SM, et al: Soluble ErbB3
levels in bone marrow and plasma of men with prostate cancer. Clin
Cancer Res. 14:3729–3736. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen N, Ye XC, Chu K, Navone NM, Sage EH,
Yu-Lee LY, Logothetis CJ and Lin SH: A secreted isoform of ErbB3
promotes osteonectin expression in bone and enhances the
invasiveness of prostate cancer cells. Cancer Res. 67:6544–6548.
2007. View Article : Google Scholar : PubMed/NCBI
|
